INFECTIOUS DISEASE RESEARCH INSTITUTE
1616 EASTLAKE AVE E NO 400, SEATTLE, WA 98102 www.idri.org

---

Organizations Filed Purposes: AS A "NONPROFIT BIOTECH," IDRI COMBINES THE HIGH-QUALITY SCIENCE OF A RESEARCH ORGANIZATION WITH THE PRODUCT DEVELOPMENT CAPABILITIES OF A BIOTECH COMPANY TO CREATE NEW DIAGNOSTICS, DRUGS AND VACCINES FOR INFECTIOUS DISEASES AND IMPROVE THE HEALTH OF THE WORLD.

DEVELOP VACCINES, ADJUVANTS, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF GLOBAL IMPORTANCE.

VACCINE RESEARCH - IDRI SCIENTISTS ARE DEVELOPING INNOVATIVE VACCINES TO COMBAT THE DEADLIEST OF NEGLECTED TROPICAL DISEASES AS WELL AS THE MOST COMMON AND ENABLE LOCAL PRODUCTION OF THESE VACCINES. BEYOND THEIR ROLE IN PREVENTING DISEASE, THESE VACCINES CAN ALSO BE USED AS THERAPEUTIC AGENTS AND TO PREVENT RECURRENCE IN AFFECTED INDIVIDUALS. IDRI TARGETS INFECTIOUS DISEASES SUCH AS TUBERCULOSIS, LEPROSY AND LEISHMANIASIS, AS WELL AS NEWLY EMERGING THREATS INCLUDING ZIKA AND CHIKUNGUNYA. THE GOAL OF IDRI'S VACCINE WORK IS TO PRODUCE SAFE, EFFECTIVE AND LOW-COST VACCINES AND TO TRANSFER VACCINE TECHNOLOGY AND EXPERTISE TO DEVELOPING COUNTRIES TO DELIVER VACCINES TO THE PEOPLE WHO NEED THEM THE MOST. IDRI SCIENTISTS ARE DEVELOPING AND MANUFACTURING NEXT GENERATION VACCINES INCLUDING THOSE BASED ON RNA TECHNOLOGY, TO RESPOND QUICKLY WHEN DISEASE OUTBREAKS OCCUR. IDRI HAS A ROBUST PIPELINE OF NEW VACCINE CANDIDATES WHICH ARE MOVING SUCCESSFULLY THROUGH EARLY CLINICAL TRIALS.

TUBERCULOSIS DRUG DISCOVERY - IDRI'S TUBERCULOSIS DRUG DISCOVERY GROUP IS FOCUSED ON DISCOVERING AND DEVELOPING NOVEL DRUGS THAT ARE EFFECTIVE AT CURING DRUG SENSITIVE AND DRUG RESISTANT TB WITH THE ADDED GOAL OF SHORTENING THE TIME IT TAKES TO CURE DISEASE. TO DATE, SCIENTISTS AT IDRI HAVE SCREENED MORE THAN HALF A MILLION COMPOUNDS, CONTINUING THE IDENTIFICATION OF NEW LEADS AND DRUG TARGETS TO COMBAT TB. IDRI IS A FOUNDING MEMBER OF THE LILLY TB DRUG DISCOVERY INITIATIVE - HEADQUARTERED AT IDRI - AND THE TB DRUG ACCELERATOR (TBDA). THE LILLY INITIATIVE IS A UNIQUE PUBLIC-PRIVATE PARTNERSHIP WITH ELI LILLY AND COMPANY AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), PART OF THE NATIONAL INSTITUTES OF HEALTH (NIH), WITH A FOCUS ON THE DISCOVERY OF NEW ANTI-TUBERCULOSIS DRUGS. THE TBDA WAS FOUNDED AS A PARTNERSHIP OF SEVEN PHARMACEUTICAL COMPANIES AND FIVE OTHER ORGANIZATIONS, FUNDED IN PART BY THE BILL & MELINDA GATES FOUNDATION, TO TARGET THE DISCOVERY OF NEW TB DRUGS BY COLLABORATING ON EARLY-STAGE DRUG DISCOVERY FOR TUBERCULOSIS.

ADJUVANT RESEARCH - ADJUVANTS ARE POWERFUL SYNTHETIC SUBSTANCES WHICH CAN BE ADDED TO VACCINES TO ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. IDRI SCIENTISTS ARE PIONEERS IN OPTIMIZING ADJUVANT AND VACCINE FORMULATIONS AND IDRI POSSESS THE WORLD'S LEADING PORTFOLIO OF ADJUVANT FORMULATIONS. THEY PROVIDE A KEY BENEFIT TO VACCINE DEVELOPMENT BY: IMPROVING IMMUNE RESPONSE, BROADENING VACCINE PROTECTION AND REDUCING THE AMOUNT OF VACCINE NEEDED. IDRI SCIENTISTS HAVE DEVELOPED MOLECULES THAT STIMULATE AN EARLY WARNING IN THE BODY'S IMMUNE SYSTEM CAUSING A POWERFUL, BROAD IMMUNE RESPONSE TO DEFINED ANTIGENS. THEY ARE FOCUSING ON HOW THAT STIMULATION TRANSLATES INTO BROAD PROTECTION AGAINST VARIOUS PATHOGENS AND HELPS REDUCE THE REQUIRED VACCINE DOSE AND NUMBER OF SHOTS A PATIENT MAY NEED. IDRI'S DEEP EXPERIENCE IN ADJUVANT DEVELOPMENT PROVIDES A UNIQUE DEPTH OF KNOWLEDGE OF REGULATORY REQUIREMENTS OF BOTH US AND FOREIGN REGULATORY AGENCIES.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202110399349300821_public.xml